Plain-English translation of NCT06137144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called for people with lymphoma and other blood cancers that have either come back after treatment or stopped responding to previous therapies. Researchers want to find the right dose and understand how well the medication works when given alone or combined with other cancer treatments. The trial will enroll about 161 people across multiple study groups designed for different types of lymphoma.
Current treatments for certain lymphomas don't work well for everyone, especially when the cancer returns or becomes resistant to standard therapies. This medication targets a specific protein involved in cancer cell growth, offering a potentially new option for patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth at a dose determined by the study, with regular visits to the clinic for blood tests, imaging scans, and check-ups to monitor your health and how well the treatment is working. The study involves multiple phases: first, researchers test increasing doses to find the safest effective level, then more participants receive the medication at that dose level. Some participants may also have biopsies taken and will need to provide tissue samples to help researchers understand how the medication affects cancer cells.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States